- Conditions
- Arginine Vasopressin Deficiency, Oxytocin Deficiency, Pediatric Disease, Hypopituitarism
- Interventions
- Norethindrone Acetate-Ethinyl Estradiol
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 7 Years to 21 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced May 22, 2026, 4:11 AM EDT